Symptomatic relief of Kirin LC-plasma shows promise as an adjunctive treatment for COVID-19

A double-blind randomized controlled trial was conducted in December 2021 at Nagasaki University Hospital as the core facility.

The results of the study were presented at the 63rd Annual Scientific Meeting of the Japanese Respiratory Society held on April 30, 2018.

A total of 100 COVID-19 patients were divided evenly between the two groups. Over a 14-day period, the LC-plasma group took 4 hard capsules containing postbiotics (400 billion units per day) and the placebo group took 4 capsules without postbiotics daily.

Changes in subjective symptoms such as cough, shortness of breath, fatigue, headache, dysosmia (partial or complete loss of smell) and dysgeusia (dysgeusia), anorexia, and chest pain were measured on a 4-point scale (no effect). is 0), 1 if little impact, 2 if impacted, 3 if impacted).

Overall score analysis showed no difference between the two groups.

However, after day 9, significantly more patients in the LC-plasma group (nearly 95%) scored 0 for olfactory and gustatory dysfunction than in the placebo group (less than 85%).
They also found that the percentage of plasmacytoid dendritic cells (pDCs) in the blood decreased significantly in the placebo group, whereas the percentage remained consistent in the LC-plasma group.

pDCs are the ‘leaders’ of immune cells that fight harmful invaders such as viruses and bacteria.

In addition, the LC-plasma group experienced a marked reduction in SARS-CoV-2 viral load from the start of treatment, whereas placebo began to show a reduction from day 4.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *